Aug 24 (Reuters) - GSK (GSK.L), opens new tab said on Monday its experimental chronic hepatitis B drug received its first global approval in Japan, and a key cancer therapy was granted a priority U.S.
H2 2026/Q1 2027 will be rich in catalysts. From the potential FDA approval of bepirovirsen, with a target action date of October 26, for the treatment of chronic hepatitis B, to the Phase 3 OCEAN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results